All In Biotech

Drug Trial Radar · NCT02980016

Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals

A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals

Last checked: Nov 19, 2026Latest source record: Oct 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,027 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,027

Actual

Start

Nov 2016

Primary completion

Oct 18, 2019

Study completion Oct 18, 2019

Sponsor

Lead sponsor
The Aurum Institute NPCAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aurum Institute; London School of Hygiene and Tropical Medicine; Johns Hopkins University
First posted
Dec 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 2 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a parallel, two part, open label, individually randomized, pragmatic trial among HIV-positive individuals. Part A compares a single round of weekly high dose rifapentine plus isoniazid for three months (3HP) to six months of daily isoniazid (6H). Part B compares periodic 3HP (p3HP) to a single round of 3HP.

Conditions

  • Tuberculosis
  • HIV

Interventions

  • rifapentine + isoniazidDrug

    Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg

  • IsoniazidDrug

    Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment completion (part A)Time frame: 1 year
  2. TB incidence (part B)Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Aurum Institute NPC

    Johannesburg, Gauteng, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.